Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 272

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 272
---
; however, the Supply Agreement has an ever-green clause and is automatically renewable for consecutive
1 year terms unless either party gives notice of termination at least 3 months prior to the then current term. The Supply Agreement may
be terminated without cause by Baxter upon 90 days’ prior written notice to the other parties. In addition, either party may terminate
the Supply Agreement in the event of an uncured material breach or insolvency.

<div align='center'>F-22</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 9:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

| 4. | In January 2024, the Company renewed its facility lease agreement until December 2024. The monthly                 
 rental obligations under non-cancellable leases are approximately $5.5 (including $3 for administrative expenses). |

As part of the agreement, the Company
has provided the landlord with a bank guarantee of approximately of $7 (NIS 27 thousand) which is valid until February 2025.

Future minimum lease payments under non-cancelable
operating leases as of December 31, 2024 are as follows:

| 2025 |     | USD | 66 |
|:-----|:----|:----|---:|
|      |     | $   | 66 |

The Company has elected to utilize the
practical expedient in ASC 842 for short-term leases (less than 12 months) whereby a lease liability and right of use asset will not
be recorded for short-term leases.

| 5. | In                                                                                                                                           
 2019, a disagreement has arisen between the Company and CSL Behring GmbH, or CSL, whether certain unshipped minimum purchase commitments     
 for fibrinogen from 2018 to 2020 are to be paid by the Company pursuant to a Framework Supply Agreement dated March 8, 2016, or Framework    
 Supply Agreement, by and between the Company and CSL, whereby CSL agreed to supply the Company with fibrinogen. On January 14, 2020,         
 the Company received a termination letter, or CSL Termination Letter. In the CSL Termination Letter, CSL demanded a total amount             
 of $820, claiming it was owed the minimum purchase commitment amounts under the Framework Supply Agreement not paid by the Company           
 in 2018 and 2019. In a subsequent correspondence